Flint Jonathan A

CIK 000129567614 companiesWALTHAM, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001295676

Recent Transactions

50 trades

Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Warrants
2020-05-05−118→ 0 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh+1,176→ 20,701 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series B Convertible Preferred Stock
2020-05-05−43,966→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-4 Convertible Preferred Stock
2020-05-05−7,693,406→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05+19,370→ 19,370 total
Sale
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh−182→ 19,525 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-3 Convertible Preferred Stock
2020-05-05−167,809→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-4 Convertible Preferred Stock
2020-05-05−52,700→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-2 Convertible Preferred Stock
2020-05-05−32,961→ 0 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$8.63/sh+118→ 6,925 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-2 Convertible Preferred Stock
2020-05-05−22,580→ 0 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$8.63/sh+173→ 10,109 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-2 Convertible Preferred Stock
2020-05-05−64,237→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-3 Convertible Preferred Stock
2020-05-05−58,980→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-3 Convertible Preferred Stock
2020-05-05−86,101→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/C Convertible Preferred Stock
2020-05-05−6,268,687→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series B Convertible Preferred Stock
2020-05-05−6,418,387→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-4 Convertible Preferred Stock
2020-05-05−149,944→ 0 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Warrants
2020-05-05−337→ 0 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh+60,308→ 1,062,259 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$8.63/sh+337→ 19,707 total
Sale
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh−94→ 10,015 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh+603→ 10,618 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/C Convertible Preferred Stock
2020-05-05−62,687→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-3 Convertible Preferred Stock
2020-05-05−8,610,081→ 0 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$8.63/sh+17,304→ 1,011,285 total
Sale
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh−9,334→ 1,001,951 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/C Convertible Preferred Stock
2020-05-05−42,941→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05+6,807→ 6,807 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05+993,981→ 993,981 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series B Convertible Preferred Stock
2020-05-05−64,183→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-2 Convertible Preferred Stock
2020-05-05−3,296,014→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series B Convertible Preferred Stock
2020-05-05−125,094→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05+9,936→ 9,936 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series C Convertible Preferred Stock
2020-05-05−1,988,991→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-4 Convertible Preferred Stock
2020-05-05−76,934→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series C Convertible Preferred Stock
2020-05-05−38,765→ 0 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Warrants
2020-05-05−173→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/C Convertible Preferred Stock
2020-05-05−122,177→ 0 total
Sale
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh−64→ 6,861 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series C Convertible Preferred Stock
2020-05-05−13,625→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series C Convertible Preferred Stock
2020-05-05−19,890→ 0 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh+413→ 7,274 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Warrants
2020-05-05−17,304→ 0 total
Sale
Phreesia, Inc.$PHR
Common Stock
2019-12-17$24.48/sh−2,360→ 21,245 total
Sale
Phreesia, Inc.$PHR
Common Stock
2019-12-17$24.48/sh−344,599→ 3,101,386 total
Sale
Phreesia, Inc.$PHR
Common Stock
2019-12-17$24.48/sh−3,446→ 31,015 total
Sale
Phreesia, Inc.$PHR
Common Stock
2019-12-17$24.48/sh−6,716→ 60,446 total
Conversion
Phreesia, Inc.$PHR
Common Stock
2019-07-22+38,289→ 38,289 total
Conversion
Phreesia, Inc.$PHR
Common Stock
2019-07-22+3,828,872→ 3,828,872 total

Companies

Recent Filings

4
Polaris Venture Management Co. V, L.L.C.
May 6, 2020

Address

C/O POLARIS VENTURE PARTNERS 1000 WINTER STREET, SUITE 3350

WALTHAM, MA, 02451

View on SEC.gov